Piper Sandler Resumes Supernus Coverage With Overweight Rating

Enna Lee

1 min read

Add as a preferred source on Google

Piper Sandler Resumes Supernus Coverage With Overweight Rating

The firm set a $47 price target and linked its view to the merger with Indivior announced in August.

By Enna Lee

Published Nov 5, 2026, 6:29 AM EST

Two unmarked pharmaceutical vials meet on a clean laboratory surface / TokenPost.ai

Piper Sandler resumed coverage of Supernus Pharmaceuticals (SUPN) on Wednesday, Nov. 4, with an Overweight rating and a $47 price target, tying its view to the company’s announced merger with Indivior.

The firm said combining the businesses would expand the merged company’s capacity for business development and acquisitions compared with what Supernus and Indivior could pursue separately.

Enna Lee

Reporter

Enna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.